Emergent complications following donepezil switchover to galantamine in three cases of dementia with Lewy bodies

被引：2

作者：

Bhanji, NH

Gauthier, S

机构：

[1] McGill Univ, Ctr Hlth, Allan Mem Inst, Clin Psychopharmacol Unit, Montreal, PQ H3A 1A1, Canada

[2] McGill Univ, Dept Psychiat, Montreal, PQ H3A 1A1, Canada

[3] McGill Ctr Studies Aging, Montreal, PQ, Canada

来源：

JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES | 2005年 / 17卷 / 04期

关键词：

D O I：

10.1176/appi.neuropsych.17.4.552

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Delayed disease progression and symptomatic improvement occur with cholinesterase inhibitors (ChEIs) in dementia with Lewy bodies (DLB). In this study, complications (insomnia, dyskinesias, agitation, and delirium) occurred in three patients switched from donepezil to galantamine. The authors describe evidence-based recommendations for ChEI switchover in DLB.

引用

收藏

页码：552 / 555

页数：4

相关论文

共 15 条

[1] Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil [J].

Auriacombe, S ;

Pere, JJ ;

Loria-Kanza, Y ;

Vellas, B .

CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (03) :129-138

[2] Advances in the treatment of Alzheimer's disease: Benefits of dual cholinesterase inhibition [J].

Ballard, CG .

EUROPEAN NEUROLOGY, 2002, 47 (01) :64-70

[3]

Cummings JL, 1997, NEUROLOGY, V48, pS10, DOI DOI 10.1212/WNL.48.5_SUPPL_6.10S

[4] Long-term use of rivastigmine in patients with dementia with Lewy bodies: An open-label trial [J].

Grace, J ;

Daniel, S ;

Stevens, T ;

Shankar, KK ;

Walker, Z ;

Byrne, EJ ;

Butler, S ;

Wilkinson, D ;

Woolford, J ;

Waite, J ;

McKeith, IG .

INTERNATIONAL PSYCHOGERIATRICS, 2001, 13 (02) :199-205

[5] Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies [J].

Holmes, C ;

Cairns, N ;

Lantos, P ;

Mann, A .

BRITISH JOURNAL OF PSYCHIATRY, 1999, 174 :45-50

[6] Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study [J].

McKeith, I ;

Del Ser, T ;

Spano, P ;

Emre, M ;

Wesnes, K ;

Anand, R ;

Cicin-Sain, A ;

Ferrara, R ;

Spiegel, R .

LANCET, 2000, 356 (9247) :2031-2036

[7] Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop [J].

McKeith, IG ;

Galasko, D ;

Kosaka, K ;

Perry, EK ;

Dickson, DW ;

Hansen, LA ;

Salmon, DP ;

Lowe, J ;

MIrra, SS ;

Byrne, EJ ;

Lennox, G ;

Quinn, NP ;

Edwardson, JA ;

Ince, PG ;

Bergeron, C ;

Burns, A ;

Miller, BL ;

Lovestone, S ;

Collerton, D ;

Jansen, ENH ;

Ballard, C ;

deVos, RAI ;

Wilcock, GK ;

Jellinger, KA ;

Perry, RH .

NEUROLOGY, 1996, 47 (05) :1113-1124

[8] What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia [J].

Minett, TSC ;

Thomas, A ;

Wilkinson, LM ;

Daniel, SL ;

Sanders, J ;

Richardson, J ;

Littlewood, E ;

Myint, P ;

Newby, J ;

McKeith, IG .

INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2003, 18 (11) :988-993

[9]

*NICE, 2001, 19 NICE

[10] NEOCORTICAL CHOLINERGIC ACTIVITIES DIFFERENTIATE LEWY BODY DEMENTIA FROM CLASSICAL ALZHEIMERS-DISEASE [J].

PERRY, EK ;

HAROUTUNIAN, V ;

DAVIS, KL ;

LEVY, R ;

LANTOS, P ;

EAGGER, S ;

HONAVAR, M ;

DEAN, A ;

GRIFFITHS, M ;

MCKEITH, IG ;

PERRY, RH .

NEUROREPORT, 1994, 5 (07) :747-749